Hepcidin-25 is a Marker of the Response Rather than Resistance to Exogenous Erythropoietin in Chronic Kidney Disease/Chronic Heart Failure Patients
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims: Erythropoietin (EPO) resistance, an important cause of anaemia in patients with heart and renal failure, is associated with increased mortality. The hypothesis of the present study was that exogenous EPO decreases hepcidin levels and that the decrease in hepcidin levels upon EPO treatment is related to the bone marrow response. Methods and results: In the EPOCARES trial, patients with renal failure (glomerular filtration rate 20–70 mL/min), heart failure, and anaemia were randomized to receive 50 IU/kg/week EPO (n = 20) or not (n = 13). Haemoglobin (Hb), hepcidin-25, ferritin, reticulocytes, serum transferrin receptor (sTfR), IL-6, and high-sensitivity C-reactive protein were measured at baseline and during treatment. Hepcidin-25 was measured by weak cation exchange chromatography/matrix assisted laser desorption ionization time-of-flight mass spectrometry. Baseline hepcidin levels were increased compared with a healthy reference population and were inversely correlated with Hb (r2 = 0.18, P = 0.02), and positively with ferritin (r2 = 0.51, P < 0.001), but not with renal function, high-sensitivity C-reactive protein or IL-6. Erythropoietin treatment increased reticulocytes (P < 0.001) and sTfR (P < 0.001), and decreased hepcidin (P < 0.001). Baseline hepcidin levels and the magnitude of the decrease in hepcidin correlated with the increase in reticulocytes (r2 = 0.23, P = 0.03) and sTfR (r2 = 0.23, P = 0.03) and also with the Hb response after 6 months (r2 = 0.49, P = 0.001). Conclusion: In this group of patients with combined heart and renal failure and anaemia, increased hepcidin levels were associated with markers of iron load and not with markers of inflammation. The (change in) hepcidin levels predicted early and long-term bone marrow response to exogenous EPO. In our group hepcidin seems to reflect iron load and response to EPO rather than inflammation and EPO resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Hepcidin inhibits the efflux of iron into plasma transferrin by downregulating ferroportin, the efflux channel for iron in macrophages and in enterocytes.(6) Enhanced synthesis of hepcidin thus leads to inhibition of iron absorption in the small intestine and sequestering of iron in macrophages, resulting in limited i…”
BackgroundWRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0908355 · Cited by 2,083
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854
Immunoassay for human serum hepcidin
Ganz, T., Olbina, G., Girelli, D., Nemeth, E., & Westerman, M. (2008) · Blood · doi:10.1182/blood-2008-02-139915 · Cited by 688
Tanno, T., Porayette, P., Sripichai, O., Noh, S.-J., Byrnes, C., Bhupatiraju, A., Lee, Y. T., Goodnough, J. B., Harandi, O., Ganz, T., et al. (2009) · Blood · doi:10.1182/blood-2008-12-195503 · Cited by 352
Cited by
Ponikowski, P., van Veldhuisen, D. J., Comin-Colet, J., Ertl, G., Komajda, M., Mareev, V., McDonagh, T., Parkhomenko, A., Tavazzi, L., Levesque, V., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu385 · Cited by 1,242
Macdougall, I. C., Bircher, A. J., Eckardt, K.-U., Obrador, G. T., Pollock, C. A., Stenvinkel, P., Swinkels, D. W., Wanner, C., Weiss, G., Chertow, G. M., et al. (2016) · Kidney International · doi:10.1016/j.kint.2015.10.002 · Cited by 482
Self-citationRonco, C., Cicoira, M., & McCullough, P. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.01.077 · Cited by 422
Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives
Jankowska, E. A., von Haehling, S., Anker, S. D., Macdougall, I. C., & Ponikowski, P. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs224 · Cited by 399
“Interestingly, in clinical settings of HF, there was no association between pro-inflammatory activation (as evidenced by circulating IL-6) and hepcidin levels.(107,108) Anaemic HF patients have reduced serum and urine hepcidin compared with non-anaemic and healthy subjects, which is accompanied by depleted total body…”
BackgroundIron status in patients with chronic heart failure
Jankowska, E. A., Malyszko, J., Ardehali, H., Koc-Zorawska, E., Banasiak, W., von Haehling, S., Macdougall, I. C., Weiss, G., McMurray, J. J. V., Anker, S. D., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/ehs377 · Cited by 273
Metadata
- Authors
- van der Putten, K., Jie, K. E., van den Broek, D., Kraaijenhagen, R. J., Laarakkers, C., Swinkels, D. W., Braam, B., & Gaillard, C. A.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09-01
- Volume
- 12
- Issue
- 9
- Pages
- 943-950
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2003478281
- Cited by
- 82
- References
- 6
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepcidin-25 is a Marker of the Response Rather than Resistance to Exogenous Erythropoietin in Chronic Kidney Disease/Chronic Heart Failure Patients. https://app.cochat.ai/papers/10.1093/eurjhf/hfq099
- The paper
- van der Putten, K., Jie, K. E., van den Broek, D., Kraaijenhagen, R. J., Laarakkers, C., Swinkels, D. W., Braam, B., & Gaillard, C. A. (2010). Hepcidin-25 is a Marker of the Response Rather than Resistance to Exogenous Erythropoietin in Chronic Kidney Disease/Chronic Heart Failure Patients. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfq099
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.